Runge Elliot, Kou Chung-Ting J, Rendo Matthew, Lynch David, Fenderson Joshua
Internal Medicine, Brooke Army Medical Center, San Antonio, USA.
Hematology and Oncology, Brooke Army Medical Center, San Antonio, USA.
Cureus. 2021 Apr 10;13(4):e14409. doi: 10.7759/cureus.14409.
Hemophagocytic lymphohistiocytosis (HLH) is a severe systemic inflammatory syndrome that is often fatal. In the adult population, it is believed to develop secondary to immune dysregulation due to rheumatologic, infectious, malignant, and recently, immunomodulatory drugs. It's co-occurrence with phagocytosis by non-macrophage cells has not been previously well defined. We present a case of lenalidomide-associated HLH with concurrent plasma cell hemophagocytosis in a patient with controlled multiple myeloma (MM).
噬血细胞性淋巴组织细胞增生症（HLH）是一种严重的全身性炎症综合征，通常会致命。在成年人群中，人们认为它继发于因风湿性、感染性、恶性以及最近出现的免疫调节药物导致的免疫失调。此前，它与非巨噬细胞的吞噬作用同时出现的情况尚未得到明确界定。我们报告了一例来那度胺相关的HLH病例，该病例发生在一名多发性骨髓瘤（MM）病情得到控制的患者身上，同时伴有浆细胞噬血细胞现象。
